Tony Hung

I started my career at Everest Clinical Research in CDM. I later joined Gilead’s CDM team focusing on infectious disease therapeutic area. I transitioned to commercial (sales analytics) for almost 3 years to better understand the lifecycle of drug post approval. I decided to return to CDM and joined Biomarin to better understand rare diseases. Post Biomarin, I spent some time at Nektar before landing the position at Denali, focusing on rare disease trials again.